Testing effectiveness (Phase 2)Study completedNCT02030834
What this trial is testing
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Who this might be right for
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
University of Pennsylvania 63